TOPLINE: In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line produced similar health outcomes and reduced costs by €22,764 per patient. METHODOLOGY: In this study, 1050 women (median age…
Leave a Comment Leave a Comment
